This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients

This study has been completed.
Proteus Digital Health, Inc.
Quintiles, Inc.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: March 21, 2011
Last updated: February 20, 2017
Last verified: February 2017
The main purpose of this exploratory trial is to evaluate the reliability, safety and usability of the Transplantation Sensor System when the Ingestible Event Marker (IEM) is given in combination with ECMPS 360 mg tablets in adult renal transplant recipients.

Condition Intervention Phase
Detection Accuracy Patient Compliance Drug: ECMPS-IEM Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Supportive Care
Official Title: A 3-month, Exploratory, Non-randomized, Multi-center, Open Label Study to Evaluate the Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • To assess the reliability of the Raisin technology defined as accuracy and precision in detecting directly observed ingestion of ECMPS-IEM and Placebo-IEM. [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • the adherence (taking and scheduling) to prescribed ECMPS-IEM schedule with and without active feedback for two consecutive periods of 8 and 4 weeks each. [ Time Frame: 12 weeks ]
  • the incidence and severity of adverse events observed during the utilization of the ECMPS-IEM and Proteus Personal Monitor (patch). [ Time Frame: 12 weeks ]
  • the satisfaction and usability of the TSS by patients [ Time Frame: 12 weeks ]

Estimated Enrollment: 30
Actual Study Start Date: May 10, 2011
Study Completion Date: November 18, 2011
Primary Completion Date: November 18, 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ECMPS-IEM Drug: ECMPS-IEM


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients at least 6 months post-transplantation and in stable clinical condition
  • Treatment with ECMPS doses between 720 mg/day and 1440 mg/day or MMF doses between1000 mg/day and 2000 mg/day, divided in two equal doses 12 hours apart and with no dose titrations planned for the duration of the trial
  • Ability to independently take medication
  • Successfully ingest a Placebo-IEM capsule with no difficulty

Exclusion Criteria:

  • Inability to use the mobile phone provided for use in the clinical trial
  • Any episodes of acute rejection in the previous 3 months
  • Presence of cognitive impairment
  • Active alcohol or drug abuse
  • History of dysphagia, or inflammatory bowel disease, or gastrointestinal conditions or surgery that has modified the normal luminal flow of the gastrointestinal tract (e.g. Whipple procedure, bariatric surgery or Roux-en-Y)
  • Known allergies, including history of skin reactions to patches, that could preclude safe participation in the study Other protocol-defined inclusion/exclusion criteria may apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01320358

Kantonspital Aarau AG / Nephrologie
Aarau, Switzerland, 5001
University Hospital Basel
Basel, Switzerland, 4000
Inselspital Bern / Nephrology
Bern, Switzerland, 3010
Stadtspital Waid Zurich
Zurich, Switzerland, 8037
University Hospital Zurich
Zurich, Switzerland, 8091
Sponsors and Collaborators
Novartis Pharmaceuticals
Proteus Digital Health, Inc.
Quintiles, Inc.
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Additional Information:
Responsible Party: Novartis Pharmaceuticals Identifier: NCT01320358     History of Changes
Other Study ID Numbers: CPRO400A2201
Study First Received: March 21, 2011
Last Updated: February 20, 2017

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Patient compliance
renal maintenance

Additional relevant MeSH terms:
Mycophenolate mofetil
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on August 16, 2017